Beijing Haijinge medicine Science-tech CO. Report issue

Government Phase 2 Phase 3

Organization Overview

First Clinical Trial
2007
NCT00544518
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Beijing Haijinge medicine Science-tech CO.,LTD(CRO) | Beijing Haijinge Pharmaceutical Technology Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

borneol (1 trial)

Drugs in Phase 2 Trials (2)

benfluorex (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3